I’d now like to hand over to Peer Schatz. Thank you.
Yeah. Thank you, John, and a warm thank you to all of you for making it down here to Dallas to the AMP 2011 meeting. It’s an extremely important meeting for our industry. We’ve been very active here since many, many years. I’d also like to say a special thanks to everybody participating on the webcast. Some, I saw, actually are dialing in from Europe, and I’d like to thank them for their energy late in the evening for this as well.
I wanted to structure my presentation today into four different topics. The first is, I wanted to show you, in what operating environment we’re actually active – the opportunities for our company going forward, as defined by macro trends.Then I’d describe, in a second session, how we are going to benefit from these trends through active development and commercialization programs. I’ll talk then about the growth opportunities in a little bit more detail – select growth opportunities, and then talk about how we’re going to translate that growth into shareholder value going forward. Today, the molecular revolution has started. It is clearly evident. If you walk the halls of the AMP conference, molecular technologies have taken front and center stage. This was not the case a few years ago. For those of you who have been here 10 years ago, it was not about molecular technologies or not nearly as visible as it is today, and it has changed dramatically. And it will continue to change going forward, as molecular technologies are creating a substantial benefit for the world of pathology and in that for the whole healthcare industry. And this is extremely important, because we are moving towards a very difficult situation in healthcare overall – aging population and tremendous pressures for better, safer treatments, increasing efficacies and costs driving the decisions in the healthcare world more than ever. And scientific advances are happening at a breakneck speed.
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts